文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型冠状病毒肺炎（COVID-19）疫苗：腺病毒载体。

COVID-19 Vaccines: Adenoviral Vectors.

机构信息

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA; email:

Harvard Medical School, Boston, Massachusetts 02115, USA.

出版信息

Annu Rev Med. 2022 Jan 27;73:41-54. doi: 10.1146/annurev-med-012621-102252. Epub 2021 Oct 5.

DOI:10.1146/annurev-med-012621-102252
PMID:34609905
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8795482/
Abstract

The worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the unprecedented pace of development of multiple vaccines. This review evaluates how adenovirus (Ad) vector platforms have been leveraged in response to this pandemic. Ad vectors have been used in the past for vaccines against other viruses, most notably HIV and Ebola, but they never have been produced, distributed, or administered to humans at such a large scale. Several different serotypes of Ads encoding SARS-CoV-2 Spike have been tested and found to be efficacious against COVID-19. As vaccine rollouts continue and the number of people receiving these vaccines increases, we will continue to learn about this vaccine platform for COVID-19 prevention and control.

摘要

由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）全球大流行，导致多种疫苗以前所未有的速度发展。这篇综述评估了腺病毒（Ad）载体平台如何应对这一大流行。腺病毒载体过去曾被用于针对其他病毒（尤其是 HIV 和埃博拉病毒）的疫苗，但从未以如此大规模的方式在人类中生产、分发或使用。已经测试了几种编码 SARS-CoV-2 刺突蛋白的不同血清型 Ad，发现它们对 COVID-19 有效。随着疫苗的推出和接种这些疫苗的人数不断增加，我们将继续了解这种用于 COVID-19 预防和控制的疫苗平台。

相似文献

[1]
COVID-19 Vaccines: Adenoviral Vectors.

Annu Rev Med. 2022-1-27

[2]
Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?

Virus Res. 2021-9

[3]
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.

Front Cell Infect Microbiol. 2021

[4]
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.

Rev Med Virol. 2021-5

[5]
The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.

Viruses. 2023-1-11

[6]
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.

J Virol. 2021-11-9

[7]
Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.

Antiviral Res. 2023-8

[8]
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.

Mol Ther. 2021-8-4

[9]
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.

Immunol Rev. 2022-9

[10]
Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.

Inflamm Res. 2022-6

引用本文的文献

[1]
Global cis-regulatory landscape of double-stranded DNA viruses.

bioRxiv. 2025-7-20

[2]
Heterologous prime-boost immunization based on a human adenovirus 5 vectored containing Trichinella spiralis Cystatin-like protein elicits protective mucosal immunity in mice.

PLoS Negl Trop Dis. 2025-7-16

[3]
[Platform technologies in vaccine development].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025-4

[4]
Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8 T cell control of tumor challenge in mice.

J Immunother Cancer. 2024-12-18

[5]
Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation.

PeerJ. 2024-12-6

[6]
Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.

Eng Microbiol. 2024-2-8

[7]
FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries.

Mol Ther Methods Clin Dev. 2024-10-18

[8]
Tolerability of a piezoelectric microneedle electroporator in human subjects.

Bioeng Transl Med. 2024-3-14

[9]
Exploration of Gene Therapy for Alport Syndrome.

Biomedicines. 2024-5-23

[10]
Incidence and management of the main serious adverse events reported after COVID-19 vaccination.

Pharmacol Res Perspect. 2024-6

本文引用的文献

[1]
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.

Nat Commun. 2021-7-26

[2]
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.

N Engl J Med. 2021-9-2

[3]
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.

Lancet. 2021-7-17

[4]
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.

N Engl J Med. 2021-9-23

[5]
Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine.

Ann Intern Med. 2021-10

[6]
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.

Nature. 2021-8

[7]
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.

Nature. 2021-8

[8]
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.

JAMA. 2021-7-6

[9]
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.

Lancet Infect Dis. 2021-8

[10]
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.

Science. 2021-8-13

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索